Cancer

Cover image for Vol. 121 Issue 5

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 159
  1. Original Articles

    1. Disease Site

      Head and Neck Disease
      Methylation status of HPV16 E2-binding sites classifies subtypes of HPV-associated oropharyngeal cancers

      Miriam Reuschenbach, Christian U. Huebbers, Elena-Sophie Prigge, Justo Lorenzo Bermejo, Martin S. Kalteis, Simon F. Preuss, Inga M.C. Seuthe, Jutta Kolligs, Ernst-Jan M. Speel, Nadine Olthof, Bernd Kremer, Steffen Wagner, Jens P. Klussmann, Svetlana Vinokurova and Magnus von Knebel Doeberitz

      Article first published online: 2 MAR 2015 | DOI: 10.1002/cncr.29315

      The methylation status of regulatory regions in the human papillomavirus (HPV) genome (E2-binding sites) is associated with the viral physical status and might explain deregulated viral oncogene expression in the presence of E2. Furthermore, the methylation status could be of prognostic significance among patients with HPV-associated oropharyngeal squamous cell cancers.

    2. Genitourinary Disease
      Circulating vitamin D, vitamin D–related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

      Irene M. Shui, Alison M. Mondul, Sara Lindström, Konstantinos K. Tsilidis, Ruth C. Travis, Travis Gerke, Demetrius Albanes, Lorelei A. Mucci, Edward Giovannucci, Peter Kraft and for the Breast and Prostate Cancer Cohort Consortium Group

      Article first published online: 2 MAR 2015 | DOI: 10.1002/cncr.29320

      Because of the high prevalence of prostate cancer (PCa) and the wide international variation in vitamin D status, identifying causal links between the two could have a large public health impact. Few studies have addressed the risk of fatal PCa. In this study, a convincing association is not observed between circulating 25-hydroxyvitamin D (25(OH)D) or single-nucleotide polymorphisms (SNPs) in key vitamin D–related genes and fatal PCa. However, interactions between biologically relevant SNPs and circulating 25(OH)D with respect to fatal PCa may deserve further investigation.

  2. Review Articles

    1. The RET oncogene in papillary thyroid carcinoma

      Jason D. Prescott and Martha A. Zeiger

      Article first published online: 2 MAR 2015 | DOI: 10.1002/cncr.29044

      The rearranged in transformation/papillary thyroid carcinoma (RET/PTC) fusion proteins play a key oncogenic role in the development of some papillary thyroid carcinomas. For this reason, the elucidation and subsequent targeting of mechanisms whereby such proteins mediate their oncogenic effects remains an important area of research.

  3. Original Articles

    1. Discipline

      Pediatric Oncology
      Osteochondroma in long-term survivors of high-risk neuroblastoma

      Brian H. Kushner, Stephen S. Roberts, Danielle N. Friedman, Deborah Kuk, Irina Ostrovnaya, Shakeel Modak, Kim Kramer, Ellen M. Basu and Nai-Kong V. Cheung

      Article first published online: 27 FEB 2015 | DOI: 10.1002/cncr.29316

      Osteochondromas in long-term survivors of neuroblastoma should be expected because these benign growths can occur within or outside radiation fields and these patients undergo radiologic studies over the course of years. A pathogenic role for chemotherapy, anti-GD2 monoclonal antibodies, or isotretinoin remains speculative.

  4. Review Articles

    1. Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue

      Sangmi Kim, Brian J. Miller, Michael E. Stefanek and Andrew H. Miller

      Article first published online: 27 FEB 2015 | DOI: 10.1002/cncr.29302

      This review examines the increasing data that implicate the indoleamine 2,3-dioxygenase pathway in the etiology of cancer-related fatigue, and it explores potential translational implications for novel treatments for cancer-related fatigue.

  5. Original Article

    1. Disease Site

      Hematologic Malignancies
      Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries

      Ivan V. Litvinov, Michael T. Tetzlaff, Elham Rahme, Youssef Habel, David R. Risser, Pamela Gangar, Michelle A. Jennings, Kevin Pehr, Victor G. Prieto, Denis Sasseville and Madeleine Duvic

      Article first published online: 27 FEB 2015 | DOI: 10.1002/cncr.29301

      To the authors' knowledge, the current study is the first to document the existence of geographic clustering as well as areas spared by cutaneous T-cell lymphoma in Texas. The results strongly argue for the existence of an external trigger for this malignancy.

  6. Original Articles

    1. Discipline

      Epidemiology
      Validity of anthropometric measurements for characterizing obesity among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study

      Robyn E. Karlage, Carmen L. Wilson, Nan Zhang, Sue Kaste, Daniel M. Green, Gregory T. Armstrong, Leslie L. Robison, Wassim Chemaitilly, Deo Kumar Srivastava, Melissa M. Hudson and Kirsten K. Ness

      Article first published online: 27 FEB 2015 | DOI: 10.1002/cncr.29300

      Skinfold measurements and waist-to-height ratios are valid and easily administered alternatives to the body mass index for the classification of body composition abnormalities in childhood cancer survivors. Clinicians should be aware of the risk of false-negative misclassification of obesity when they are using the body mass index in this population. Those exposed to cranial radiation are at particular risk.

    2. Outcomes Research
      Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis

      Caitriona B. O'Neill, Shrujal S. Baxi, Coral L. Atoria, James P. O'Neill, Martin C. Henman, Eric J. Sherman, Nancy Y. Lee, David G. Pfister and Elena B. Elkin

      Article first published online: 27 FEB 2015 | DOI: 10.1002/cncr.29262

      In older patients, the rates of acute toxicities and feeding tube use in patients receiving chemotherapy and radiation therapy can potentially be considerable. It is possible that for certain older patients, the potential benefit of adding chemotherapy to radiation therapy does not outweigh the harms of this combined-modality therapy.

    3. Disease Site

      Gastrointestinal Disease
      Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer

      Abdul K. Siraj, Sarita Prabhakaran, Prashant Bavi, Rong Bu, Shaham Beg, Mohsen Al Hazmi, Maha Al-Rasheed, Mohammed Al-Assiri, Rami Sairafi, Fouad Al-Dayel, Nasser Al-Sanea, Shahab Uddin and Khawla S. Al-Kuraya

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29288

      This comprehensive study will help in implementing a universal screening/reflex testing strategy for Lynch syndrome in a clinical setting among patients with colorectal cancer in Saudi Arabia and in conducting a national screening program benefitting both patients and their relatives.

  7. Correspondence

    1. Reply to Wilms tumor and breast cancer

      Norman E. Breslow, Susan M. Peterson and Daniel M. Green

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29278

  8. Original Articles

    1. Disease Site

      Head and Neck Disease
      Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates

      Allen S. Ho, Louise Davies, Iain J. Nixon, Frank L. Palmer, Laura Y. Wang, Snehal G. Patel, Ian Ganly, Richard J. Wong, R. Michael Tuttle and Luc G. T. Morris

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29289

      Modern medical practices now uncover previously undiagnosed small thyroid cancers and artificially improve survival rates but leave mortality rates unchanged. Relying on survival data to measure success in treating thyroid cancer unnecessarily reinforces aggressive diagnostic and therapeutic practices.

  9. Correspondence

    1. Wilms tumor and breast cancer

      Steven Lehrer and Kenneth E. Rosenzweig

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29279

    2. Reply to Wilms tumor and breast cancer

      Jennifer B. Dean and Jeffrey S. Dome

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29281

  10. Original Articles

    1. Discipline

      Outcomes Research
      Reference values of the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being: A report from the American Cancer Society's studies of cancer survivors

      Alexis R. Munoz, John M. Salsman, Kevin D. Stein and David Cella

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29286

      The current study provides reference values from a representative sample of the US adult cancer survivor population. These data will aid researchers and clinicians with interpreting the magnitude and meaning of their own findings on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being; The 12-item Spiritual Well-Being Scale (FACIT-Sp-12) measure and allow for comparisons of scores across groups in trials.

    2. Symptom Control and Palliative Care
      Automated pain intervention for underserved minority women with breast cancer

      Karen O. Anderson, Guadalupe R. Palos, Tito R. Mendoza, Charles S. Cleeland, Kai-Ping Liao, Michael J. Fisch, Araceli Garcia-Gonzalez, Alyssa G. Rieber, L. Arlene Nazario, Vicente Valero, Karin M. Hahn, Cheryl L. Person and Richard Payne

      Article first published online: 24 FEB 2015 | DOI: 10.1002/cncr.29204

    3. Outcomes Research
      The role of families in decisions regarding cancer treatments

      Gabriela S. Hobbs, Mary Beth Landrum, Neeraj K. Arora, Patricia A. Ganz, Michelle van Ryn, Jane C. Weeks, Jennifer W. Mack and Nancy L. Keating

      Article first published online: 23 FEB 2015 | DOI: 10.1002/cncr.29064

      In this large study of patients with newly diagnosed lung or colorectal cancer, the majority of patients reported involving family members in treatment decisions. Non-English-speaking Asian and Hispanic patients were particularly likely to rely on family for decision-making.

  11. Editorial

    1. A review of incidence and relevant risk factors in genitourinary malignancies

      Marie B. Tobin and Gary D. Steinberg

      Article first published online: 17 FEB 2015 | DOI: 10.1002/cncr.29273

      In the current issue of Cancer, Klaassen et al have identified an increased risk of suicide in 4 of 5 genitourinary malignancies, with an especially high risk noted in patients with bladder and kidney cancer. This study identified older age, male sex, single/widowed/divorced status, white race, aggressive disease, and increased surgical intervention as risk factors for increased suicide risk in patients with genitourinary malignancies.

  12. Original Articles

    1. Discipline

      Psychosocial Oncology
      Factors associated with suicide in patients with genitourinary malignancies

      Zachary Klaassen, Rita P. Jen, John M. DiBianco, Lael Reinstatler, Qiang Li, Rabii Madi, Ronald W. Lewis, Arthur M. Smith, Durwood E. Neal Jr, Kelvin A. Moses and Martha K. Terris

      Article first published online: 17 FEB 2015 | DOI: 10.1002/cncr.29274

      Suicide in patients with genitourinary malignancies, particularly those with bladder, kidney, and prostate cancer, poses a public health dilemma. Clinicians should be aware of risk factors for suicide in these patients, especially among men, the elderly, and those with aggressive disease.

    2. Translational Research
      Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases

      Stefan Stremitzer, Wu Zhang, Dongyun Yang, Yan Ning, Sebastian Stintzing, Ana Sebio, Yu Sunakawa, Shinichi Yamauchi, Satoshi Matsusaka, Rita El-Khoueiry, Judith Stift, Friedrich Wrba, Thomas Gruenberger and Heinz-Josef Lenz

      Article first published online: 17 FEB 2015 | DOI: 10.1002/cncr.29259

      Variations in genes involved in angiopoietin and pericyte pathways that may become escape mechanisms under antivascular endothelial growth factor-targeted therapy are investigated in a unique cohort of patients with resectable colorectal liver metastases who received perioperative bevacizumab-based chemotherapy and underwent liver resection in curative intent. Genetic variants in RALBP1, PDGFB, and ANGPT2 were associated with response, recurrence-free survival, overall survival, and the probability of achieving a cure and may serve as predictive and/or prognostic biomarkers in patients who are treated using a multidisciplinary approach.

  13. Review Article

    1. New oral small molecules in the treatment of chronic lymphocytic leukemia

      Nicole Lamanna

      Article first published online: 17 FEB 2015 | DOI: 10.1002/cncr.29130

      There has been a dramatic change in therapy for chronic lymphocytic leukemia over the last 20 years. The current study provides a review of some of the new small molecule inhibitors being used in the treatment of patients with chronic lymphocytic leukemia, with a focus on the B-cell receptor signaling-associated kinases (Bruton tyrosine kinase, phosphatidylinositol 3-kinase, and spleen tyrosine kinase) as well as inhibition of Bcl-2.

  14. Editorial

    1. Genetic variants and response to cancer treatments

      Janindra Warusavitarne, Justin Stebbing and Omar Faiz

      Article first published online: 17 FEB 2015 | DOI: 10.1002/cncr.29257

      The authors discuss new findings that single nucleotide polymorphisms in genes associated with off-target effects of antiangiogenesis agents have a bearing on clinical outcomes. This, in turn, reveals potential new targets for drug development.

  15. Original Articles

    1. Discipline

      Quality of Life
      Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study

      Josée Savard, Hans Ivers, Marie-Hélène Savard and Charles M. Morin

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29244

      This study showed that cancer treatments are associated with increased insomnia, an effect that is mediated by somatic symptoms. It emphasizes the importance of managing appropriately treatment side effects in order to prevent the occurrence and aggravation of insomnia in this population.

    2. Disease Site

      Gastrointestinal Disease
      Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study

      Davendra P.S. Sohal, Shiva Shrotriya, Kate Tullio Glass, Robert J. Pelley, Michael J. McNamara, Bassam Estfan, Marc Shapiro, Jane Wey, Sricharan Chalikonda, Gareth Morris-Stiff, R. Matthew Walsh and Alok A. Khorana

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29298

      Baseline patient-related clinical and laboratory parameters can predict high mortality after surgical resection in patients with pancreatic adenocarcinoma. Patients undergoing routine clinical care can be identified early through this approach.

    3. Hematologic Malignancies
      Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma

      Jessica N. Williams, Ashish Rai, Joseph Lipscomb, Jean L. Koff, Loretta J. Nastoupil and Christopher R. Flowers

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29290

      Treatment with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for >4 cycles appears to yield optimal survival among patients with diffuse large B-cell lymphoma who are aged >80 years, even after controlling for comorbid diseases, performance status, and Ann Arbor stage of disease. Use of the regimen of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) for >4 cycles also appears to be an effective treatment for patients in this age group with Ann Arbor stage III/IV disease.

    4. Discipline

      Outcomes Research
      Residential racial segregation and mortality among black, white, and Hispanic urban breast cancer patients in Texas, 1995 to 2009

      Sandi L. Pruitt, Simon J. Craddock Lee, Jasmin A. Tiro, Lei Xuan, John M. Ruiz and Stephen Inrig

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29282

      Residential racial segregation is adversely associated with mortality among urban women with breast cancer in Texas, does not explain the main effect of race/ethnicity on mortality after adjustment for tumor, patient, and neighborhood covariates, and its effects may differ by patient race/ethnicity.

    5. Disease Site

      Melanoma
      Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma

      Maki Yamamoto, Kate J. Fisher, Joyce Y. Wong, Jonathan M. Koscso, Monique A. Konstantinovic, Nicholas Govsyeyev, Jane L. Messina, Amod A. Sarnaik, C. Wayne Cruse, Ricardo J. Gonzalez, Vernon K. Sondak and Jonathan S. Zager

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29239

      Sentinel lymph node biopsy is indicated for the staging of patients with clinically lymph node-negative melanoma of intermediate thickness, but its use is controversial in patients with thick melanoma. The results of the current study indicate that sentinel lymph node biopsy in patients with thick melanoma appears to have prognostic value in determining overall, disease-specific, and recurrence-free survival.

    6. Discipline

      Psychosocial Oncology
      When do we need to care about the caregiver? Supportive care needs, anxiety, and depression among informal caregivers of patients with cancer and cancer survivors

      Halina Sklenarova, Arne Krümpelmann, Markus W. Haun, Hans-Christoph Friederich, Johannes Huber, Michael Thomas, Eva C. Winkler, Wolfgang Herzog and Mechthild Hartmann

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29223

      This study introduces a family perspective to cancer. It describes that caregivers' emotional well-being is also significantly affected and presents detailed information on their needs for support.

  16. Editorial

    1. The time is now: Assessing and addressing the needs of cancer caregivers

      Teresa L. Deshields and Allison J. Applebaum

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29226

      Informal caregivers are essential to the current system of delivery for cancer care, yet research indicates that these caregivers are distressed and endorse many unmet needs. Further research is needed to identify how to best address the supportive care needs of this population.

  17. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Patient beliefs that chemotherapy may be curative and care received at the end of life among patients with metastatic lung and colorectal cancer

      Jennifer W. Mack, Anne Walling, Sydney Dy, Anna Liza M. Antonio, John Adams, Nancy L. Keating and Diana Tisnado

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29250

      An understanding of the purpose of chemotherapy for incurable cancer is a critical aspect of informed consent. Patients with advanced cancer who are well informed about chemotherapy's goals receive late-life chemotherapy at rates similar to those for other patients, but they are more likely to enroll in hospice before death. This suggests important care outcomes beyond chemotherapy use.

  18. Correspondence

    1. Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

      Susan Halabi, Brian I. Rini, Bernard Escudier, Walter M. Stadler and Eric J. Small

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29252

  19. Review Article

    1. Improving access to novel agents for childhood leukemia

      Weili Sun, Paul S. Gaynon, Richard Sposto and Alan S. Wayne

      Article first published online: 11 FEB 2015 | DOI: 10.1002/cncr.29267

      The complex biology and aggressive nature of childhood leukemia, coupled with the relatively small patient population available for study, pose specific challenges to the development of new therapies. In this review, the authors discuss strategies and initiatives designed to improve access to new agents and early phase clinical trials for pediatric leukemia.

  20. Correspondence

  21. Original Articles

    1. Discipline

      Symptom Control and Palliative Care
      Bedside clinical signs associated with impending death in patients with advanced cancer: Preliminary findings of a prospective, longitudinal cohort study

      David Hui, Renata dos Santos, Gary Chisholm, Swati Bansal, Camila Souza Crovador and Eduardo Bruera

      Article first published online: 9 FEB 2015 | DOI: 10.1002/cncr.29048

      In this prospective, longitudinal, observational study, 8 highly specific physical signs associated with death within 3 days among cancer patients are identified. These telltale signs may inform the diagnosis of impending death and clinical decision making.

    2. Clinical Trials
      Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

      Maysa M. Abu-Khalaf, Megan A. Baumgart, Scott N. Gettinger, Indukala Doddamane, David P. Tuck, Shihe Hou, Nianhang Chen, Catherine Sullivan, Kimberly Lezon-Geyda, Daniel Zelterman, Christos Hatzis, Hari Deshpande, Michael P. Digiovanna, Masoud Azodi, Peter E. Schwartz and Lyndsay N. Harris

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29254

      Sirolimus shows an acceptable safety profile and promising activity at a weekly dose of 40 mg with nab-paclitaxel (100 mg/m2), with better responses seen in patients with a higher posttreatment AKT score and an early reduction in [18F]fludeoxyglucose activity.

    3. Epidemiology
      The past, present, and future of cancer incidence in the United States: 1975 through 2020

      Hannah K. Weir, Trevor D. Thompson, Ashwini Soman, Bjørn Møller and Steven Leadbetter

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29258

      Between 2010 and 2020, the cancer incidence rates/risk is predicted to stabilize for much of the US population. However, we expect the number of cancer cases to increase substantially. A greater emphasis on primary prevention and early detection is needed to counter the effect of an aging and growing population on the burden of cancer.

    4. Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study

      Evan J. Walker, Andrew H. Ko, Elizabeth A. Holly and Paige M. Bracci

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29256

      The association between statin use and pancreatic cancer risk is poorly understood. In this large case-control study, statin use is associated with a decreased risk of pancreatic cancer in men, and the duration of use is inversely associated with risk.

    5. Pediatric Oncology
      Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: A report from the Childhood Cancer Survivor Study

      Casey L. Daniel, Connie L. Kohler, Kayla L. Stratton, Kevin C. Oeffinger, Wendy M. Leisenring, John W. Waterbor, Kimberly F. Whelan, Gregory T. Armstrong, Tara O. Henderson, Kevin R. Krull, Leslie L. Robison and Paul C. Nathan

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29265

      Less than 30% of childhood cancer survivors in the current study cohort who were considered to be at an increased risk of colorectal cancer were screened as recommended. Educational interventions targeted at survivors and their primary care physicians are needed to increase awareness of survivors' increased risk of colorectal cancer due to radiation exposure and appropriate surveillance.

    6. Disease Site

      Hematologic Malignancies
      Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies

      Jean El-Cheikh, Roberto Crocchiolo, Sabine Furst, Stefania Bramanti, Barbara Sarina, Angela Granata, Andrea Vai, Claude Lemarie, Catherine Faucher, Bilal Mohty, Samia Harbi, Reda Bouabdallah, Norbert Vey, Armando Santoro, Christian Chabannon, Luca Castagna and Didier Blaise

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29271

      Alternative donors, such as unrelated umbilical cord blood and related haploidentical donors, are more and more frequently searched for and used for patients who are candidates for allogeneic hematopoietic stem cell transplantation but are without a suitable related or unrelated donor. In the current study, comparison of umbilical cord blood and haploidentical donor grafts suggests that, for patients with high-risk hematological diseases without a related or unrelated donor, haploidentical transplants are a promising alternative option that deserves further investigation.

  22. Erratum

    1. You have free access to this content
    2. You have free access to this content
  23. Original Articles

    1. Disease Site

      Chest and Lung Disease
      Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis

      Kathryn P. Lowry, G. Scott Gazelle, Michael E. Gilmore, Colden Johanson, Vidit Munshi, Sung Eun Choi, Angela C. Tramontano, Chung Yin Kong and Pamela M. McMahon

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29225

      A microsimulation model was used to evaluate the health benefits of hypothetical lung cancer screening programs targeting individuals with chronic obstructive pulmonary disease compared with programs with eligibility based on smoking history alone. Programs incorporating lower pack-year thresholds for individuals with COPD achieved the highest life expectancy per number of screens.

  24. Review Articles

    1. Infertility in reproductive-age female cancer survivors

      Jennifer M. Levine, Joanne Frankel Kelvin, Gwendolyn P. Quinn and Clarisa R. Gracia

      Article first published online: 3 FEB 2015 | DOI: 10.1002/cncr.29181

      This review summarizes risks for infertility in reproductive-age females with cancer, presents options for fertility preservation, addresses psychosocial issues, raises ethical issues, and outlines considerations for developing an institutional fertility preservation program.

  25. Original Articles

    1. Discipline

      Clinical Trials
      A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies

      John F. Deeken, Hongkun Wang, Deepa Subramaniam, Aiwu Ruth He, Jimmy Hwang, John L. Marshall, Christina E. Urso, Yiru Wang, Corinne Ramos, Kenneth Steadman and Michael J. Pishvaian

      Article first published online: 29 JAN 2015 | DOI: 10.1002/cncr.29224

      Acquired resistance to anti-EGFR monoclonal antibody therapy may be caused by EGFR-ErbB2 dimer formation in tumor cells. The authors conduct this phase 1 trial combining cetuximab and lapatinib to determine the recommended dose and safety of combining dual EGFR and ErbB2 therapies.

  26. Correspondence

    1. Critical evaluation of the scientific content in clinical practice guidelines

      Andres Cervantes, George Pentheroudakis and Dirk Arnold

      Article first published online: 29 JAN 2015 | DOI: 10.1002/cncr.29261

  27. Original Articles

    1. Discipline

      Outcomes Research
      Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children

      Raymond Mailhot Vega, Jane Kim, Abby Hollander, Jona Hattangadi-Gluth, Jeff Michalski, Nancy J. Tarbell, Torunn I. Yock, Marc Bussiere and Shannon M. MacDonald

      Article first published online: 29 JAN 2015 | DOI: 10.1002/cncr.29209

      Although proton therapy is costly, it may sometimes be cost effective compared with traditional photon therapy, especially when treating pediatric tumors. The authors present data regarding strategy favorability between proton versus photon radiotherapy for pediatric brain tumors and analyze the cost effectiveness and the risk and cost of growth hormone deficiency with specific dose comparisons between modalities.

    2. Disease Site

      Head and Neck Disease
      Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis

      N. Gopalakrishna Iyer, Daniel S.W. Tan, Veronique KM Tan, Weining Wang, Jacqueline Hwang, Ngian-Chye Tan, Ranjiv Sivanandan, Hiang-Khoon Tan, Wan Teck Lim, Mei-Kim Ang, Joseph Wee, Khee-Chee Soo and Eng Huat Tan

      Article first published online: 29 JAN 2015 | DOI: 10.1002/cncr.29251

      The 10-year update of a trial comparing concurrent chemotherapy and radiotherapy with surgery and adjuvant radiotherapy in patients with stage III/IV nonmetastatic head and neck squamous cell carcinoma is presented. Subset analysis demonstrates that surgery with adjuvant radiotherapy is superior to concurrent chemotherapy and radiotherapy in patients with advanced resectable squamous cell carcinoma arising from the oral cavity and maxillary sinus.

    3. Gastrointestinal Disease
      Variation in hospital treatment patterns for metastatic colorectal cancer

      Robert W. Krell, Scott E. Regenbogen and Sandra L. Wong

      Article first published online: 29 JAN 2015 | DOI: 10.1002/cncr.29253

      Wide variation in hospital treatment patterns for patients with metastatic colorectal cancer has been stable over time. It appears that much of the approach for the treatment of metastatic colorectal cancer depends on the hospital in which the patient presents.

  28. Commentary

    1. Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon?

      Emmanouil Fokas, Torsten Liersch, Rainer Fietkau, Werner Hohenberger, Clemens Hess, Heinz Becker, Rolf Sauer, Christian Wittekind and Claus Rödel

      Article first published online: 21 JAN 2015 | DOI: 10.1002/cncr.29260

      Although downstaging after neoadjuvant treatment is increasingly used as a prognostic factor and surrogate endpoint in clinical trials, the current study directly questions its value after preoperative treatment when assessing treatment efficacy.

  29. Original Articles

    1. Discipline

      Clinical Trials
      Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

      John D. Hainsworth, Gedske Daugaard, Thierry Lesimple, Gerdt Hübner, F. Anthony Greco, Michael J. Stahl, Christian Meyer Zum Büschenfelde, Djelila Allouache, Nicolas Penel, Poul Knoblauch and Karim S. Fizazi

      Article first published online: 21 JAN 2015 | DOI: 10.1002/cncr.29229

      The addition of belinostat to combined paclitaxel and carboplatin does not improve the progression-free survival of patients with carcinoma of unknown primary site who receive first-line therapy, although patients who receive belinostat have a higher investigator-assessed response rate.

    2. Disease Site

      Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer

      Bo Yang, Lin Cao, Jiaen Liu, Yanjie Xu, Gillian Milne, Wanhei Chan, Steven D. Heys, Colin D. McCaig and Jin Pu

      Article first published online: 20 JAN 2015 | DOI: 10.1002/cncr.29235

      The level of chloride channel accessory 1 expression may be a potential predictor of prognosis in primary human colorectal cancer. Low expression of chloride channel accessory 1 predicts disease recurrence and lower survival, and this has implications for the selection of patients most likely to need and benefit from adjuvant chemotherapy.

    3. Discipline

      Medical Oncology
      Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration

      Doreen A. Ezeife, Tony H. Truong, Daniel Y. C. Heng, Sylvie Bourque, Stephen A. Welch and Patricia A. Tang

      Article first published online: 20 JAN 2015 | DOI: 10.1002/cncr.29246

      The drug approval timeline, from regulatory agency submission to approval, is 3 months shorter for the US Food and Drug Administration than for Health Canada. The median time from Health Canada approval to the placement of a drug on a provincial formulary is 16.7 months.

    4. Disease Site

      Breast Disease
      Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium

      Kimberly H. Allison, Linn A. Abraham, Donald L. Weaver, Anna N. A. Tosteson, Heidi D. Nelson, Tracy Onega, Berta M. Geller, Karla Kerlikowske, Patricia A. Carney, Laura E. Ichikawa, Diana S. M. Buist and Joann G. Elmore

      Article first published online: 20 JAN 2015 | DOI: 10.1002/cncr.29199

      Based on diagnostic results of breast biopsies from the BCSC from women undergoing mammography between 1996 and 2008, the frequencies of biopsy after screening mammography did not change over time, whereas diagnoses of DCIS and invasive cancer increased, suggesting more targeted use of biopsy. Among biopsies following mammography, women with dense breasts or family history of breast cancer were more likely to have high-risk lesions or invasive cancer.

  30. Review Articles

    1. The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal of the published literature and National Comprehensive Cancer Network guidelines

      Parul Sinha, Jay F. Piccirillo, Dorina Kallogjeri, Edward L. Spitznagel and Bruce H. Haughey

      Article first published online: 14 JAN 2015 | DOI: 10.1002/cncr.29242

      The National Comprehensive Cancer Network's category 1 recommendation for the addition of chemotherapy to postoperative radiation in patients with oropharynx cancer is based on a hypothesis-generating subset analysis, and not high-level evidence. The current National Comprehensive Cancer Network guideline for adjuvant therapy does not inform human papillomavirus-related oropharynx cancer management.

  31. Original Articles

    1. Disease Site

      Breast Disease
      Flat epithelial atypia and risk of breast cancer: A Mayo cohort study

      Samar M. Said, Daniel W. Visscher, Aziza Nassar, Ryan D. Frank, Robert A. Vierkant, Marlene H. Frost, Karthik Ghosh, Derek C. Radisky, Lynn C. Hartmann and Amy C. Degnim

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29243

      Based on its cytologic features, and its cooccurrence with atypical hyperplasia and breast cancer, flat epithelial atypia has been proposed as a precursor lesion on the pathway to the development of breast cancer. However, it appears to be a benign proliferative finding of the breast that does not convey an independent risk of future breast cancer.

    2. Head and Neck Disease
      Pretreatment Dysphagia Inventory and videofluorographic swallowing study as prognostic indicators of early survival outcomes in head and neck cancer

      Chan Joo Yang, Jong-Lyel Roh, Kyoung Hyo Choi, Min-Ju Kim, Seung-Ho Choi, Soon Yuhl Nam and Sang Yoon Kim

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29245

      Associations between pretreatment MD Anderson Dysphagia Inventory or videofluorographic swallowing study results and treatment outcomes are evaluated in patients with head and neck squamous cell carcinoma. The total score, global assessment, and subdomains of the MD Anderson Dysphagia Inventory are significantly predictive of early survival outcomes in patients with head and neck squamous cell carcinoma.

    3. Genitourinary Disease
      Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer

      Stéphane Terry, Nathalie Nicolaiew, Victor Basset, Fannie Semprez, Pascale Soyeux, Pascale Maillé, Francis Vacherot, Guillaume Ploussard, Arturo Londoño-Vallejo, Alexandre de la Taille and Yves Allory

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29233

      The development of biomarkers may be helpful to estimate tumor heterogeneity and stratify prostate cancer patients in terms of risk of progression. The results from this study suggest that ERG and TFF3 characterize 2 distinct subsets of prostate cancer, including a more aggressive subgroup for TFF3 tumors that express SPINK1, supporting a rationale of screening for these biomarkers for prognostic purposes and molecular subtyping of the disease.

    4. Discipline

      Disparities Research
      Patient navigation based on predictive modeling decreases no-show rates in cancer care

      Sanja Percac-Lima, Patrick R. Cronin, David P. Ryan, Bruce A. Chabner, Emily A. Daly and Alexandra B. Kimball

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29236

      Targeted patient navigation over the telephone to patients determined by predictive modeling to be at high risk of being no-shows for appointments can effectively and substantially increase patient adherence to cancer clinic appointments and improve adherence to cancer care.

    5. Radiation Oncology
      Proton therapy for low-grade gliomas: Results from a prospective trial

      Helen A. Shih, Janet C. Sherman, Lisa B. Nachtigall, Mary K. Colvin, Barbara C. Fullerton, Juliane Daartz, Barbara K. Winrich, Tracy T. Batchelor, Lauren T. Thornton, Sarah M. Mancuso, Michele K. Saums, Kevin S. Oh, William T. Curry, Jay S. Loeffler and Beow Y. Yeap

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29237

      Patients with low-grade glioma can safely and effectively receive proton radiation therapy with no added neurocognitive impairment or quality-of-life decrement based on early experience. Radiation dose to the pituitary correlates with early neuroendocrine dysfunction.

    6. Disease Site

      Head and Neck Disease
      Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey

      David I. Rosenthal, Abdallah S. R. Mohamed, Randal S. Weber, Adam S. Garden, Parag R. Sevak, Merril S. Kies, William H. Morrison, Jan S. Lewin, Adel K. El-Naggar, Lawrence E. Ginsberg, Esengul Kocak-Uzel, K. Kian Ang and Clifton David Fuller

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29241

      Total laryngectomy followed by postoperative radiotherapy can produce long-term cancer control and survival for patients with T4 larynx cancer. The selection of patients for nonsurgical initial treatment should be done carefully because of significant rates of functional impairment and locoregional failure.

    7. An audit and feedback system for effective quality improvement in head and neck surgery: Can we become better surgeons?

      Carol M. Lewis, Marcus M. Monroe, Dianna B. Roberts, Amy C. Hessel, Stephen Y. Lai and Randal S. Weber

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29238

      After an initial audit, individual surgeons are provided with their own performance data and anonymized departmental performance. A subsequent audit reveals a significant decrease in the postoperative length of stay and the prevalence of negative performance indicators.

    8. Discipline

      Clinical Trials
      Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

      Jorge E. Cortes, Hagop M. Kantarjian, Delphine Rea, Meir Wetzler, Jeffrey H. Lipton, Luke Akard, H. Jean Khoury, Mauricette Michallet, Agnès Guerci-Bresler, Charles Chuah, Andrzej Hellmann, Raghunadharao Digumarti, Purvish M. Parikh, Laurence Legros, Krzysztof Warzocha, Michele Baccarani, Elizabeth Li, Mihaela Munteanu and Franck E. Nicolini

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29240

      Final efficacy and safety data for omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia with at least 24 months of follow-up are presented from the pivotal Chronic Myeloid Leukemia 300 study. The results suggest that the long-term administration of omacetaxine is feasible and that omacetaxine provides durable hematologic and cytogenetic responses in some patients.

    9. Radiation Oncology
      A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non–small cell lung cancer (NSCLC)

      Wataru Takahashi, Mio Nakajima, Naoyoshi Yamamoto, Hideomi Yamashita, Keiichi Nakagawa, Tadaaki Miyamoto, Hiroshi Tsuji, Tadashi Kamada and Takehiko Fujisawa

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29195

      Carbon ion therapy shows promise as a monotherapy in patients with inoperable locally advanced non–small cell lung cancer who are not candidates for concurrent chemoradiotherapy. We achieved 51.9% overall 2-year survival rates, with this modality.

    10. Pediatric Oncology
      EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study

      Amanda M. Li, Christopher Dunham, Uri Tabori, Anne-Sophie Carret, P. Daniel McNeely, Donna Johnston, Lucie Lafay-Cousin, Beverly Wilson, David D. Eisenstat, Nada Jabado, Shayna Zelcer, Mariana Silva, Katrin Scheinemann, Christopher Fryer, Glenda Hendson, Abbas Fotovati, Cynthia Hawkins, Stephen Yip, Sandra E. Dunn and Juliette Hukin

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29198

      Expression levels of several biomarkers are investigated in pediatric intracranial ependymomas, and enhancer of zeste homolog 2 (EZH2) expression is independently associated with poor survival. Thus, EZH2 is identified as a novel prognostic factor in pediatric intracranial ependymoma.

    11. Disease Site

      Gastrointestinal Disease
      Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib

      Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S. Rosen, Beatrice Seddon, Suayib Yalcin, Hans Gelderblom, Charles C. Williams Jr, Elena Fumagalli, Guido Biasco, Herbert I. Hurwitz, Pamela E. Kaiser, Kolette Fly, Ewa Matczak, Liang Chen, Maria José Lechuga and George D. Demetri

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29220

      Final results from a worldwide treatment-use study of sunitinib in gastrointestinal stromal tumor (GIST) add to the existing body of evidence supporting the long-term safety and efficacy of sunitinib in an international population of patients with advanced GIST after failure on first-line imatinib who were ineligible for other sunitinib clinical trials. These data expand results reported in the more restricted and selected population of patients accrued to the phase 3 study of sunitinib in GIST.

  32. Review Articles

    1. Screening and early detection efforts in lung cancer

      Neeti M. Kanodra, Gerard A. Silvestri and Nichole T. Tanner

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29222

      Since publication of the National Lung Screening Trial, several professional organizations, including the US Preventive Services Task Force, have published guidelines recommending low-dose computed tomography for screening in asymptomatic, high-risk individuals. Recommendations for lung cancer screening include risks, benefits, costs, and future directions in the efforts for early detection.

  33. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care

      Vasu Sunkara and James R. Hébert

      Article first published online: 8 JAN 2015 | DOI: 10.1002/cncr.29228

      The mortality-to-incidence ratio helps to identify disparities in colorectal cancer screening and treatment internationally. It has the potential to be an indicator of the long-term success of colorectal cancer surveillance programs, with possible extension to other cancer types.

    2. Head and Neck Disease
      Second primary head and neck cancer after Hodgkin lymphoma: A population-based study of 44,879 survivors of Hodgkin lymphoma

      Amit K. Chowdhry, Colin McHugh, Chunkit Fung, Sughosh Dhakal, Louis S. Constine and Michael T. Milano

      Article first published online: 8 JAN 2015 | DOI: 10.1002/cncr.29231

      There is a significantly increased risk of salivary and nonsalivary head and neck cancer after a diagnosis of Hodgkin lymphoma. Survivors of Hodgkin lymphoma with squamous cell head and neck cancer experience worse survival outcomes.

    3. Discipline

      Epidemiology
      Teenage acne and cancer risk in US women: A prospective cohort study

      Mingfeng Zhang, Abrar A. Qureshi, Renée T. Fortner, Susan E. Hankinson, Qingyi Wei, Li-E Wang, A. Heather Eliassen, Walter C. Willett, David J. Hunter and Jiali Han

      Article first published online: 8 JAN 2015 | DOI: 10.1002/cncr.29216

      We identify a history of teenage acne as a novel risk factor for melanoma independent of the previously identified risk factors. Our findings may provide novel insight into the etiology of melanoma. In addition, a history of acne may be an early-stage marker of high androgen levels, which might have potential importance to help identify populations at higher risk of hormone-related cancers.

    4. Disease Site

      Endocrine Disease
      Trends in imaging after diagnosis of thyroid cancer

      Jaime L. Wiebel, Mousumi Banerjee, Daniel G. Muenz, Francis P. Worden and Megan R. Haymart

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29210

      Using the Surveillance, Epidemiology, and End Results-Medicare database, the authors report that despite a rise in low-risk differentiated thyroid cancer, there has been a significant increase in the use of postdiagnosis imaging studies over the past 20 years. This is true for the 3 major imaging modalities used (neck ultrasound, radioiodine scan, and positron emission tomography), with the most dramatic increase noted in the use of positron emission tomography after 2004.

    5. Hepatobiliary Disease
      A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

      Mairéad G. McNamara, Lisa W. Le, Anne M. Horgan, Alex Aspinall, Kelly W. Burak, Neesha Dhani, Eric Chen, Mehrdad Sinaei, Glen Lo, Tae Kyoung Kim, Patrik Rogalla, Oliver F. Bathe and Jennifer J. Knox

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29227

      With second-line axitinib treatment, tumor control was established in 42.3% at 16 weeks. Axitinib showed encouraging tolerable clinical activity in vascular endothelial growth factor–pretreated hepatocellular carcinoma patients, but further study is indicated in a selected population incorporating potential biomarkers of response.

    6. Discipline

      Quality of Life
      Health-related quality of life in lung cancer survivors: Latent class and latent transition analysis

      Kelly M. Kenzik, Michelle Y. Martin, Mona N. Fouad and Maria Pisu

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29232

      According to responses on a health-related quality of life (HRQOL) questionnaire in the initial and survivorship phases of care, there are 4 subgroups (classes) of lung cancer survivors for which different HRQOL limitations are prominent, and survivors are unlikely to transition out of these classes during the survivorship phase. Classes have different survival profiles; thus, identifying which class survivors fall into during the initial phase of care is critical to developing supportive care strategies and improving long-term outcomes.

    7. Disparities Research
      Impact of patient and navigator race and language concordance on care after cancer screening abnormalities

      Marjory Charlot, M. Christina Santana, Clara A. Chen, Sharon Bak, Timothy C. Heeren, Tracy A. Battaglia, A. Patrick Egan, Richard Kalish and Karen M. Freund

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29221

      Patient navigator race and language concordance improves the timeliness of care after cancer screening in a minority population. Patient navigators who are diverse by race/ethnicity and multilingual may help address barriers to care and improve cancer outcomes for low-income minority populations.

    8. Health behaviors of minority childhood cancer survivors

      Melinda R. Stolley, Lisa K. Sharp, Christy C. Tangney, Linda A. Schiffer, Claudia Arroyo, Yoonsang Kim, Richard T. Campbell, Mary Lou Schmidt, Kathleen Breen, Karen E. Kinahan, Kim J. Dilley, Tara O. Henderson, Allen D. Korenblit and Katya Seligman

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29202

      The current study examined the health behaviors of minority childhood cancer survivors compared with white peers and noncancer controls. Overall, survivors were not different from controls, but minority survivors may be at a higher risk of adverse outcomes.

    9. Disease Site

      Chest and Lung Disease
      Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study

      Mitsugu Omasa, Hiroshi Date, Takashi Sozu, Tosiya Sato, Kanji Nagai, Kohei Yokoi, Tatsuro Okamoto, Norihiko Ikeda, Fumihiro Tanaka, Yoshimasa Maniwa and for the Japanese Association for Research on the Thymus

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29166

      Postoperative radiotherapy increases relapse-free survival for stage II and III thymic carcinoma. Postoperative radiotherapy does not increase relapse-free survival or overall survival for stage II or III thymoma.

    10. Discipline

      Disparities Research
      Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: Another long-term effect of cancer?

      Maria Pisu, Kelly M. Kenzik, Robert A. Oster, Patricia Drentea, Kimlin T. Ashing, Mona Fouad and Michelle Y. Martin

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29206

      One-year after diagnosis, approximately 1 in 2 survivors of lung cancer and colorectal cancer report economic hardship, especially African Americans. This disparity among lung cancer survivors is explained by differences in economic status; however, among colorectal cancer survivors, differences in economic status, cancer stage, and treatment do not account for the observed disparities.

  34. Editorial

    1. Postoperative radiotherapy: Not all thymic malignancies are created equal

      Andreas Rimner

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29164

      The key finding of Omasa et al.'s study is that postoperative radiotherapy is associated with an improvement in recurrence-free survival in patients with thymic carcinoma but not in patients with thymoma.

  35. Correspondence

    1. Sham procedure inadequate

      William Hay

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29114

  36. Original Articles

    1. Disease Site

      Head and Neck Disease
      Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: Results from the Pittsburgh Lung Screening Study

      Ronak Dixit, Joel L. Weissfeld, David O. Wilson, Paula Balogh, Pamela Sufka, Jill M. Siegfried, Jennifer R. Grandis and Brenda Diergaarde

      Article first published online: 5 JAN 2015 | DOI: 10.1002/cncr.29189

      Earlier diagnosis of head and neck cancer should lead to improved outcomes. However, because head and neck cancer is relatively rare, screening of the general population is impractical. Results from the current study provide a rationale for offering head and neck cancer screening along with low-dose computed tomography screening for lung cancer.

    2. Gastrointestinal Disease
      Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer

      Leticia Moreira, Jenifer Muñoz, Míriam Cuatrecasas, Isabel Quintanilla, Maria Liz Leoz, Sabela Carballal, Teresa Ocaña, María López-Cerón, Maria Pellise, Sergi Castellví-Bel, Rodrigo Jover, Montserrat Andreu, Angel Carracedo, Rosa Maria Xicola, Xavier Llor, Clement Richard Boland, Ajay Goel, Antoni Castells and Francesc Balaguer

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29190

      Somatic mutL homolog 1 (MLH1) hypermethylation occurs in up to 15% of Lynch syndrome colorectal cancers, and a meaningful proportion of potential MLH1 mutation carriers may be undiagnosed when relying on somatic MLH1 methylation for indicating germline genetic testing. This is a novel and clinically relevant result that clearly argues against the use of MLH1 methylation analysis as a negative predictor of an MLH1 germline mutation.

  37. Review Articles

    1. Therapeutic targeting of tumor suppressor genes

      Luc G. T. Morris and Timothy A. Chan

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29140

      In recent years, several promising strategies directed at tumor suppressor genes, or the pathways controlled by these genes, have emerged. Here, we describe advances in a number of different methodologies aimed at therapeutically targeting tumors driven by inactivated tumor suppressor genes.

  38. Original Articles

    1. Disease Site

      Neuro-Oncology
      Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

      Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29234

      Patients with recurrent glioblastoma who are treated with bevacizumab and develop hypertension as a side effect appear to demonstrate significantly better progression-free survival and overall survival. Therefore, bevacizumab-induced hypertension may be a physiologic marker of outcome in patients with recurrent glioblastoma.

    2. Discipline

      Pediatric Oncology
      Improving our understanding of the use of traditional complementary/alternative medicine in children with cancer

      Elena J. Ladas, Meiko Lin, Federico Antillion, Silvia Rivas, Guillermo Chantada, Walter Cacciavillano, Roberta Ortiz, Katja Stein, Luis Castillo, Valeria Rocha, Ligia Fu, Hilze Rodriquez and Kara M. Kelly

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29212

      We demonstrate the success of the development of a cross-cultural survey exploring the use of Traditional Complementary/Alternative Medicine (TCAM) in children with cancer. These findings will aid investigators in providing guidelines on TCAM, support the development of education and research priorities, and assist with the identification of region-specific variables related to use of TCAM.

    3. Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer

      Deena R. Levine, Liza-Marie Johnson, Belinda N. Mandrell, Jie Yang, Nancy K. West, Pamela S. Hinds and Justin N. Baker

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29230

      Does phase 1 trial participation impact end-of-life care characteristics among patients with cancer? This institutional retrospective review of children with cancer demonstrated no significant differences in end-of-life characteristics among those who did and those who did not enroll in a phase 1 trial.

    4. Conditional survival in pediatric malignancies: Analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program

      Ann C. Mertens, Jian Yong, Andrew C. Dietz, Erin Kreiter, Yutaka Yasui, Archie Bleyer, Gregory T. Armstrong, Leslie L. Robison and Karen Wasilewski-Masker

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29170

      Overall, conditional survival is high in 5-year survivors of pediatric cancer. For health care providers, as well as for survivors and their families, this information is clinically important when counseling patients seen during long-term follow-up.

    5. Outcomes Research
      Comparison of primary and secondary breast cancers in adolescents and young adults

      Claire Sadler and Melanie Goldfarb

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29200

      Nonprimary breast cancer in female adolescents and young adults (AYAs) has different tumor characteristics, presents at a lower stage, and receives less adjuvant therapy than primary AYA female breast cancers. Second malignancy status is an independent risk factor for decreased overall survival, with an almost 10% decrease at 3 years.

    6. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic

      Scott M. Gilbert, Rodney L. Dunn, Daniela Wittmann, Jeffrey S. Montgomery, John M. Hollingsworth, David C. Miller, Brent K. Hollenbeck, John T. Wei and James E. Montie

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29215

      Integrating patient-reported outcomes such as quality of life into the recovery care of men with prostate cancer is associated with better outcomes. These results indicate that more tailored approaches to evaluating and addressing patient-reported problems improve care and support survivorship models of care.

    7. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer

      Beibei Xu, Isabel J. Boero, Lindsay Hwang, Quynh-Thu Le, Vitali Moiseenko, Parag R. Sanghvi, Ezra E. W. Cohen, Loren K. Mell and James D. Murphy

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29207

      The results from this Surveillance, Epidemiology, End Results-Medicare–based study indicate that nearly 25% of elderly patients will develop aspiration pneumonia within 5 years of receiving chemoradiotherapy for head and neck cancer. These patients also have a significantly increased rate of death, suggesting that a better understanding of mitigating factors could help identify patients who are at risk for this potentially lethal complication.

    8. Disease Site

      Breast Disease
      Performance of digital screening mammography among older women in the United States

      Louise M. Henderson, Ellen S. O'Meara, Dejana Braithwaite, Tracy Onega and for the Breast Cancer Surveillance Consortium

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29214

      The specificity, positive predictive value, recall rate, and cancer-detection rate of digital screening mammography all improve with increasing age. The current results indicate that, as age increases, the proportion of women with invasive breast cancer versus ductal carcinoma in situ rises, whereas the proportion of women with positive lymph nodes decreases.

    9. Discipline

      Clinical Trials
      Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

      Edwin Choy, Yael Flamand, Sriram Balasubramanian, James E. Butrynski, David C. Harmon, Suzanne George, Gregory M. Cote, Andrew J. Wagner, Jeffrey A. Morgan, Mint Sirisawad, Chitra Mani, Francis J. Hornicek, Zhenfeng Duan and George D. Demetri

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29175

      In this phase 1 study, the histone deacetylase inhibitor abexinostat (PCI-24781) is administered in combination with doxorubicin to patients with metastatic sarcoma. The maximum tolerated dose for abexinostat is 45 mg/m2 twice daily when administered on days 1 through 5 with doxorubicin at a dose of 75 mg/m2 on day 4 of a 3-week cycle, and granulocyte-colony–stimulating factor support is mandated.

    10. Radiation Oncology
      You have full text access to this OnlineOpen article
      Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

      Joseph M. Herman, Daniel T. Chang, Karyn A. Goodman, Avani S. Dholakia, Siva P. Raman, Amy Hacker-Prietz, Christine A. Iacobuzio-Donahue, Mary E. Griffith, Timothy M. Pawlik, Jonathan S. Pai, Eileen O'Reilly, George A. Fisher, Aaron T. Wild, Lauren M. Rosati, Lei Zheng, Christopher L. Wolfgang, Daniel A. Laheru, Laurie A. Columbo, Elizabeth A. Sugar and Albert C. Koong

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29161

      To the authors' knowledge, the current study is the first prospective multi-institutional trial evaluating the role of stereotactic body radiotherapy in patients with locally advanced pancreatic cancer. The results suggest that fractionated stereotactic body radiotherapy with gemcitabine achieves favorable toxicity, quality of life, and preliminary efficacy compared with historical data.

    11. Complementary Medicine
      Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial

      Julienne E. Bower, Alexandra D. Crosswell, Annette L. Stanton, Catherine M. Crespi, Diana Winston, Jesusa Arevalo, Jeffrey Ma, Steve W. Cole and Patricia A. Ganz

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29194

      Women who are diagnosed with premenopausal breast cancer report higher levels of stress, distress, and physical symptoms and are less likely to participate in support groups than older women. In this study, a mindfulness-based intervention targeted for younger breast cancer survivors has excellent adherence and leads to significant short-term reductions in stress, physical symptoms, and inflammatory activity, with longer term benefits observed for cancer-related distress.

    12. Disease Site

      Head and Neck Disease
      Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis?

      Sabine Semrau, Marlen Haderlein, Daniela Schmidt, Michael Lell, Walburga Wolf, Frank Waldfahrer, Michael Uder, Heinrich Iro, Torsten Kuwert and Rainer Fietkau

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29188

      This article focuses on strategies of tumor response assessment after single-cycle chemotherapy in borderline-resectable head and neck squamous cell carcinoma before subsequent chemoradiotherapy or surgery. 18F-FDG-PET response assessment correlates better than CT-based response with endoscopic response assessment and is potentially capable of identifying more patients eligible for a conservative, organ-preserving approach than endoscopy or CT.

  39. Editorials

    1. Histone deacetylase inhibitors in cancer: What have we learnt?

      James R. Whittle and Jayesh Desai

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29177

      The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single-agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be the focus of future studies.

  40. Erratum

    1. You have free access to this content
  41. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population-based cohort study

      Jack P. Wang, Feng-Yu Kao, Chen-Yi Wu, Yi-Ping Hung, Yee Chao, Yiing-Jenq Chou and Chung-Pin Li

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29159

      Nucleos(t)ide analogues reduce the risk of hepatocellular carcinoma and overall mortality in hepatitis B carriers. The dose-response effects further strengthen the causal relationship and support the use of nucleos(t)ide analogues in patients with chronic hepatitis B.

    2. Discipline

      Disparities Research
      Are primary care providers prepared to care for survivors of breast cancer in the safety net?

      Aaron J. Dawes, Marian Hemmelgarn, David K. Nguyen, Greg D. Sacks, Sheilah M. Clayton, Jacqueline R. Cope, Patricia A. Ganz and Melinda Maggard-Gibbons

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29201

      Primary care providers working in safety-net settings report low knowledge and confidence in their ability to care for survivors of breast cancer. Additional training concerning aspects of survivorship care, including compliance with American Society of Clinical Oncology guidelines, is needed before survivors can be successfully transitioned to primary care.

VIEW

  1. 1 - 100
  2. 101 - 159

SEARCH

SEARCH BY CITATION